Literature DB >> 12079338

Reversible dimer formation and stability of the anti-tumour single-chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IR spectroscopy.

Yie Chia Lee1, Mark K Boehm, Kerry A Chester, Richard H J Begent, Stephen J Perkins.   

Abstract

MFE-23 is a single chain Fv (scFv) antibody molecule used to target colorectal cancer through its high affinity for the tumour marker carcinoembryonic antigen (CEA). ScFv molecules are formed from peptide-linked antibody V(H) and V(L) domains, and many of these form dimers. Our recent crystal structure for MFE-23 showed that this formed an unusual symmetric back-to-back association of two monomers that is consistent with a domain-swapped diabody structure. Neutron scattering and modelling fits showed that MFE-23 existed as compact V(H)-V(L)-linked monomers at therapeutically relevant concentrations below 1 mg/ml. Size-exclusion gel chromatography showed that the monomeric and dimeric forms of MFE-23 could be separated, and that the proportions of these two forms depended on the starting MFE-23 concentration. Sedimentation equilibrium experiments by analytical ultracentrifugation at nine concentrations of MFE-23 indicated a reversible monomer-dimer self-association equilibrium with an association constant of 1.9x10(3)-2.2x10(3) M(-1). Sedimentation velocity experiments using the time derivative g(s(*)) method showed that MFE-23-His has a concentration-dependent weight average sedimentation coefficient that increased from 1.8 S for the monomer to about 3-6 S for the dimer. Both values agreed with those calculated from the MFE-23 crystal structure. In relation to the thermal stability of MFE-23, denaturation experiments by (1)H NMR and FT-IR spectroscopy showed that the molecule is stable up to 47 degrees C, after which denaturation was irreversible. MFE-23 dimerisation is discussed in terms of a new model for diabody structures, in which the V(H) and V(L) domains in the monomer are able to dissociate and reassociate to form a dimer, or diabody, but in which symmetric back-to-back contacts between the two monomers are formed. This dimerisation in solution is attributed to the complementary nature of the C-terminal surface of the MFE-23 monomer. Crystal structures for seven other scFv molecules have shown that, while the contact residues for symmetric back-to-back dimer formation in MFE-23 are not fully conserved, in principle, back-to-back contacts can be formed in these too. This offers possibilities for the creation of other forms of scFv molecules. (c) 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12079338     DOI: 10.1016/S0022-2836(02)00403-5

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  11 in total

1.  High resolution NMR-based model for the structure of a scFv-IL-1beta complex: potential for NMR as a key tool in therapeutic antibody design and development.

Authors:  Ian C Wilkinson; Catherine J Hall; Vaclav Veverka; Jiye Y Shi; Frederick W Muskett; Paul E Stephens; Richard J Taylor; Alistair J Henry; Mark D Carr
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

2.  Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors.

Authors:  Martin C Boonstra; Berend Tolner; Boudewijn E Schaafsma; Leonora S F Boogerd; Hendrica A J M Prevoo; Guarav Bhavsar; Peter J K Kuppen; Cornelis F M Sier; Bert A Bonsing; John V Frangioni; Cornelis J H van de Velde; Kerry A Chester; Alexander L Vahrmeijer
Journal:  Int J Cancer       Date:  2015-06-22       Impact factor: 7.396

Review 3.  Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications.

Authors:  Eric C Peterson; W Brooks Gentry; S Michael Owens
Journal:  Adv Pharmacol       Date:  2014

4.  Ion-specific modulation of protein interactions: anion-induced, reversible oligomerization of a fusion protein.

Authors:  Yatin R Gokarn; R Matthew Fesinmeyer; Atul Saluja; Shawn Cao; Jane Dankberg; Andrew Goetze; Richard L Remmele; Linda O Narhi; David N Brems
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

5.  Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability.

Authors:  Michael M Schmidt; Greg M Thurber; K Dane Wittrup
Journal:  Cancer Immunol Immunother       Date:  2008-04-12       Impact factor: 6.968

6.  Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine.

Authors:  Eric C Peterson; Elizabeth M Laurenzana; William T Atchley; Howard P Hendrickson; S Michael Owens
Journal:  J Pharmacol Exp Ther       Date:  2008-01-11       Impact factor: 4.030

7.  Engineering a single-chain Fv antibody to alpha v beta 6 integrin using the specificity-determining loop of a foot-and-mouth disease virus.

Authors:  Heide Kogelberg; Berend Tolner; Gareth J Thomas; Danielle Di Cara; Shane Minogue; Bala Ramesh; Serena Sodha; Dan Marsh; Mark W Lowdell; Tim Meyer; Richard H J Begent; Ian Hart; John F Marshall; Kerry Chester
Journal:  J Mol Biol       Date:  2008-07-16       Impact factor: 5.469

8.  Rise and fall of an anti-MUC1 specific antibody.

Authors:  Holger Thie; Lars Toleikis; Jiandong Li; Reinhard von Wasielewski; Gunther Bastert; Thomas Schirrmann; Isabel Tourais Esteves; Christian K Behrens; Bénédict Fournes; Nathalie Fournier; Christophe de Romeuf; Michael Hust; Stefan Dübel
Journal:  PLoS One       Date:  2011-01-14       Impact factor: 3.240

9.  Cytokinergic IgE Action in Mast Cell Activation.

Authors:  Heather J Bax; Anthony H Keeble; Hannah J Gould
Journal:  Front Immunol       Date:  2012-08-06       Impact factor: 7.561

10.  Homogeneous antibody fragment conjugation by disulfide bridging introduces 'spinostics'.

Authors:  Felix F Schumacher; Vishal A Sanchania; Berend Tolner; Zoë V F Wright; Chris P Ryan; Mark E B Smith; John M Ward; Stephen Caddick; Christopher W M Kay; Gabriel Aeppli; Kerry A Chester; James R Baker
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.